Birte Nygaard1, Lars Bastholt2, Finn Noe Bennedbæk1, Tobias Wirenfeldt Klausen3, Jens Bentzen4. 1. Department of Endocrinology, Herlev University Hospital, Herlev, Denmark. 2. Department of Oncology, Odense University Hospital, Odense, Denmark. 3. Department of Haematology, Herlev University Hospital, Herlev, Denmark. 4. Department of Oncology, Herlev University Hospital, Herlev, Denmark.
Abstract
BACKGROUND: It is well known that thyroid hormone withdrawal (THW) in thyroid cancer patients can induce a decrease in quality of life (QOL). Recombinant human thyrotropin (rh-TSH) has been used to avoid this; however, no blinded studies have ever documented the effect. OBJECTIVE: To compare QOL in patients with differentiated thyroid cancer (DTC) treated with eitherrh-TSH or liothyronine (L-T3) THW for 10 days. STUDY DESIGN: Double-blind, randomised cross-over. PATIENTS: Fifty-six patients with DTC treated by total thyroidectomy and indication for postsurgeryradioiodine (RI) ablation therapy. INTERVENTION: Randomisation to either L-T3 and rh-TSH prior to the first RI course and following this to ingest placebo tablets and receive placebo injections before a second RI uptake measurement 4-6 months later, or to receive placebo before the primary RI ablation and active therapy 4-6 months later. MAIN OUTCOME MEASURES: QOL was measured by SF-36 and 2 visual analogue scale (VAS) scores at baseline and during RI therapy or RI uptake. RESULTS: A significant difference in QOL was seen in 2 of 4 predefined SF-36 domains (7.2 and 6.6%) and 2 VAS scales (10 and 14%), favouring rh-TSH therapy. CONCLUSION: This is the first blinded randomised clinical trial describing the effect of rh-TSH compared to L-T3 THW on QOL in DTC patients. A significant difference was demonstrated, though smaller than described in previous non-blinded studies.
RCT Entities:
BACKGROUND: It is well known that thyroid hormone withdrawal (THW) in thyroid cancerpatients can induce a decrease in quality of life (QOL). Recombinant human thyrotropin (rh-TSH) has been used to avoid this; however, no blinded studies have ever documented the effect. OBJECTIVE: To compare QOL in patients with differentiated thyroid cancer (DTC) treated with either rh-TSH or liothyronine (L-T3) THW for 10 days. STUDY DESIGN: Double-blind, randomised cross-over. PATIENTS: Fifty-six patients with DTC treated by total thyroidectomy and indication for postsurgery radioiodine (RI) ablation therapy. INTERVENTION: Randomisation to either L-T3 and rh-TSH prior to the first RI course and following this to ingest placebo tablets and receive placebo injections before a second RI uptake measurement 4-6 months later, or to receive placebo before the primary RI ablation and active therapy 4-6 months later. MAIN OUTCOME MEASURES: QOL was measured by SF-36 and 2 visual analogue scale (VAS) scores at baseline and during RI therapy or RI uptake. RESULTS: A significant difference in QOL was seen in 2 of 4 predefined SF-36 domains (7.2 and 6.6%) and 2 VAS scales (10 and 14%), favouring rh-TSH therapy. CONCLUSION: This is the first blinded randomised clinical trial describing the effect of rh-TSH compared to L-T3 THW on QOL in DTCpatients. A significant difference was demonstrated, though smaller than described in previous non-blinded studies.
Entities:
Keywords:
Quality of life; Recombinant human thyrotropin; Thyroid cancer; Triiodothyronine
Authors: Pamela R Schroeder; Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Steven I Sherman; David S Cooper; Kathryn G Schuff; Lewis E Braverman; Monica C Skarulis; Terry F Davies; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; Bruce D Weintraub; E Chester Ridgway; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2006-01-04 Impact factor: 5.958
Authors: Jakob B Bjorner; Gene V Wallenstein; Marie C Martin; Peggy Lin; Bonnie Blaisdell-Gross; Catherine Tak Piech; Samir H Mody Journal: Curr Med Res Opin Date: 2007-04 Impact factor: 2.580
Authors: Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw Journal: N Engl J Med Date: 2012-05-03 Impact factor: 91.245
Authors: C Dueren; M Dietlein; M Luster; F Plenzig; R Steinke; J Grimm; P Groth; W Eichhorn; C Reiners Journal: Exp Clin Endocrinol Diabetes Date: 2009-10-23 Impact factor: 2.949
Authors: Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves Journal: J Cancer Surviv Date: 2020-06-06 Impact factor: 4.442
Authors: Eva-Maria Gamper; Lisa M Wintner; Margarida Rodrigues; Sabine Buxbaum; Bernhard Nilica; Susanne Singer; Johannes M Giesinger; Bernhard Holzner; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-13 Impact factor: 9.236
Authors: Robert M Wolfson; Irina Rachinsky; Deric Morrison; Al Driedger; Tamara Spaic; Stan H M Van Uum Journal: J Oncol Date: 2016-02-09 Impact factor: 4.375